Related Experiment Video
Updated: Oct 4, 2025
09:53
Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery
Published on: July 5, 2021
3.8K
Medical Therapy for Craniopharyngiomas
Krystallenia I Alexandraki1, Paraskevi Xekouki2
1Second Department of Surgery, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Touchreviews in Endocrinology
|February 4, 2022
Summary
Targeted therapies show promise for rare craniopharyngiomas. Molecularly distinct adamantinomatous (ACP) and papillary (PCP) types respond to specific inhibitors, advancing personalized medicine for these brain tumors.
Area of Science:
- Neuro-oncology
- Molecular Pathology
- Pharmacology
Background:
- Craniopharyngiomas are rare, benign brain neoplasms with two distinct subtypes: adamantinomatous (ACP) and papillary (PCP).
- Current treatments (surgery, radiotherapy) have significant complications due to tumor location near critical brain structures.
- Advances in understanding molecular pathways driving ACP and PCP have opened avenues for targeted medical therapies.
Purpose of the Study:
- To systematically review case series and reports of patients with craniopharyngiomas treated with systemic medical therapy.
- To evaluate the efficacy and safety of emerging molecularly targeted treatments for ACP and PCP.
- To highlight the potential of personalized medicine in managing these rare tumors.
Main Methods:
- Systematic review of published case series and case reports.
- Identification of studies involving patients treated with systemic medical therapy for craniopharyngiomas.
- Analysis of treatment responses based on tumor subtype and targeted agents.
Main Results:
- ACP treatment involves MEK inhibitors (e.g., binimetinib) or anti-inflammatory agents (e.g., tocilizumab), showing favorable efficacy.
- PCP treatment utilizes BRAF inhibitors (e.g., dabrafenib) or combination therapy with MEK inhibitors (e.g., trametinib), also resulting in favorable responses.
- Ongoing trials are investigating optimal dosing, combinations, and safety profiles of these novel therapies.
Conclusions:
- Molecularly targeted therapies represent a paradigm shift in craniopharyngioma management, moving towards personalized medicine.
- Specific inhibitors targeting distinct molecular pathways in ACP and PCP offer promising therapeutic options.
- Further research and clinical trials are crucial to refine treatment strategies and ensure patient safety.
